Is NCT07285044 recruiting in Jacksonville, FL?

Yes, NCT07285044 is currently recruiting participants at its Jacksonville, FL location. This amyloidosis clinical trial is actively enrolling qualified participants.

How do I join the amyloidosis clinical trial in Jacksonville?

To join this clinical trial in Jacksonville, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Jacksonville clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Amyloidosis Clinical Trial in Jacksonville, FL

About This Amyloidosis Study in Jacksonville

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent

Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \[NCCN\], American Society of Clinical Oncology \[ASCO\], American Society of Hematology \[ASH\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines

A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician

Female or male patients age \>= 18 years at the time of consent

Willing and able to comply with the study protocol in the investigator's judgement

Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.

Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens

Eligible disease cancer types:

Amyloidosis

Basal cell carcinoma

Endometrial

Fallopian tube

Gastroesophageal

Glioblastoma

Head and neck

Hepatocellular

Hodgkin lymphoma

Mantle cell lymphoma

Merkle cell carcinoma

Multiple myeloma

Myelodysplastic syndrome

Renal cell carcinoma

Squamous cell carcinoma

Urothelial carcinoma

Eligible regimens

Atezolizumab +/- bevacizumab

Bevacizumab

Daratumumab +/- bortezomib

Darbepoetin alpha

Denosumab (Xgeva)

Fluorouracil +/- bevacizumab

Fulvestrant

Ipilimumab +/- Nivolumab

Nivolumab + relatlimab

Pembrolizumab

Pertuzumab +/- trastuzumab

Trastuzumab +/- pertuzumab

Zoledronic acid (Zometa)

Willingness to follow birth control requirements for females and males of reproductive potential

Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network

Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic

Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \>= 12 weeks from the time of registration

Provide written informed consent

Ability to complete questionnaire(s) by themselves or with assistance

Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Exclusion Criteria

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.

Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial

Individuals who require continuous (24/7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study

Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Jacksonville?

Yes, this clinical trial (NCT07285044) has an active research site in Jacksonville, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Amyloidosis Treatment Options in Jacksonville, FL

If you're searching for amyloidosis treatment options in Jacksonville, FL, this clinical trial (NCT07285044) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Jacksonville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all amyloidosis clinical trials near you to find additional studies recruiting in your area.

Amyloidosis Clinical Trial in Jacksonville, FL

Expert Care in Jacksonville

IRB Approved

No-Cost Care

Apply for This Jacksonville Location

Why Participate?

Simple Process